Galmed (NASDAQ: GLMD) unveils digital asset plan, reshapes SEDDS deal

Rhea-AI Filing Summary

Galmed Pharmaceuticals reports several corporate updates. The company issued a press release announcing a new digital asset management strategy aimed at enhancing capital efficiency and driving shareholder value. Galmed also terminated a previously announced binding term sheet with Entomus s.r.o. for an exclusive license to develop and commercialize a Self-Emulsifying Drug Delivery System (SEDDS) formulation. Instead, a new UK-based company has been formed to pursue the SEDDS project, and it is contemplated that Galmed will acquire up to 25% of this entity’s share capital, subject to definitive agreements and board approval. The company additionally filed supplemental risk factor disclosures that update prior risk discussions and incorporated these materials into its existing Form S-8 and Form F-3 registration statements.

Insights

Biopharma and capital markets analyst

Galmed reshapes a development deal and highlights a new digital asset strategy.

Galmed Pharmaceuticals is pivoting its role in an earlier SEDDS formulation arrangement. Instead of leading development under an exclusive license with Entomus s.r.o., a new UK-based company will now own and advance the SEDDS project. Galmed contemplates acquiring up to 25% of this vehicle, subject to definitive documentation and board approval, which shifts its exposure from operator to minority stakeholder.

The filing also notes a digital asset management strategy described as targeting capital efficiency and shareholder value, though detailed mechanics are contained in the referenced press release. Supplemental risk factors are being added and incorporated into existing Form S-8 and Form F-3 registration statements, signaling that the company is updating investors on potential risks tied to its evolving business and financing profile.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of August 2025

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

c/o Meitar Law Offices, 16 Abba Hillel Silver Rd.,

Ramat Gan, 5250608

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On August 25, 2025, Galmed Pharmaceuticals Ltd. (the “Company”) issued a press release entitled “Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In addition, on August 25, 2025, the Company entered into a termination agreement of a previously announced binding term sheet that was entered into with Entomus s.r.o. for an exclusive license to develop and commercialize a Self-Emulsifying Drug Delivery System (SEDDS) formulation. Following additional due diligence and discussions between the parties, the Company has decided to modify and de-risk the structure of its participation so that the Company will not lead the project. Instead, a new UK-based company has been established for the development and commercialization of the SEDDS formulation in which it is contemplated that the Company will acquire up to 25% of its share capital, subject to execution of definitive documentation and approval of the Company’s board of directors.

The Company is filing certain updated risk factors disclosure applicable to its business for the purpose of supplementing and updating disclosures contained in the Company’s prior public filings including those discussed under the heading “Item 3.D. Risk Factors” in the Company’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission on April 2, 2025. The supplemental updated risk factors are filed herewith as Exhibit 99.2 and are incorporated herein by reference.

This Form 6-K, the first three paragraphs of the press release attached hereto as Exhibit 99.1 and the supplemental risk factors attached hereto as Exhibit 99.2 are incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos. 333-206292, 333-227441 and 333-284163) and the Company’s Registration Statements on Form F-3 (Registration Nos. 333-272722 and 333-283241).

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release, dated August 25, 2025.
99.2		Supplemental Risk Factors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.
Date: August 25, 2025	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer

FAQ

What did Galmed Pharmaceuticals (GLMD) disclose in this Form 6-K?

Galmed Pharmaceuticals disclosed a new digital asset management strategy, restructured its SEDDS formulation arrangement, and filed supplemental risk factor disclosures.

What is Galmed Pharmaceuticals’ new digital asset management strategy?

Galmed announced a digital asset management strategy described as aiming to enhance capital efficiency and drive shareholder value, as detailed in a press release incorporated by reference.

How did Galmed change its SEDDS formulation agreement with Entomus s.r.o.?

Galmed terminated a previously announced binding term sheet that would have made it the project lead for an exclusive SEDDS license with Entomus s.r.o.

What is the role of the new UK-based company in the SEDDS project?

A new UK-based company has been established to develop and commercialize the SEDDS formulation, and Galmed contemplates acquiring up to 25% of its share capital, subject to definitive agreements and board approval.

What updated risk factors did Galmed Pharmaceuticals (GLMD) file?

Galmed filed supplemental updated risk factor disclosures that supplement and update those in its prior public filings, including its latest Form 20-F.

How are these disclosures linked to Galmed’s existing registration statements?

This Form 6-K, portions of the press release, and the supplemental risk factors are incorporated by reference into Galmed’s Form S-8 and Form F-3 registration statements.